Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00751166Phase 4Terminated
Phase 4, randomised, double-blind trial of desloratadine in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Organon & Co. Primary endpoint: Change from Baseline in the average AM/PM 12-hour reflective pruritus severity score at Day 7. Started Mar 2004; status: terminated.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00751166.